Background: Shuanghuang Shengbai granule is effective in curing cyclophosphamideinduced myelosuppression without promoting lung cancer development. This study aims to investigate its mechanism and therapeutic targets.
INTRODUCTION
Lung cancer is the most common cancer in men and the leading cause of cancer death in women [1] . The 5-year relative survival of lung cancer is currently 18% [2] . Especially, lung cancer diagnosed in China comprises about 33-50% of the global incidence burden. For lung cancer, 733,300 new cases and 432,400 deaths were estimated to appear in China in 2015 [3] . Cyclophosphamide (CTX) has been widely used to block the progression of lung cancer in clinic [4] . However, CTX generally causes severe acute toxicities like myelosuppression [5] . Once myelosuppression appears, patients are more likely to suffer from infection. Currently, protecting patients from CTX-induced myelosuppression is a main challenge in lung cancer treatment.
Nowadays, colony-stimulating factor, granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor are the main drugs in treating myelosuppression [6, 7] . However, these drugs can lead to lung injury, splenic rupture and vascular events, and they even promote cancer development and metastasis [8, 9] . As a traditional Chinese medicine, Shuanghuang Shengbai (SHSB) granule has been widely used in clinic for decades in China [10] . It can increase white blood cells (WBCs) and cure myelosuppression, whereas it cannot cause obvious adverse effect or cancer progression [11, 12] . Reportedly, SHSB granule can enhance the epidermal growth factor receptor signaling pathway in bone marrow and the Notch signaling pathway in bone marrow nuclear cells [13, 14] . SHSB granule can reduce the percentage of bone marrow cells (BMCs) in G0/G1 phase and increase the proliferation index of BMCs via up-regulating CDK4, CDK6 and cyclin D1 [15] . Also, it promotes the transformation of hematopoietic stem cells from G0/G1 phase to S phase via up-regulating c-Myc, cell division cycle 25A, Rb, pRb and E2F in bone marrow nuclear cells [10] . On the contrary, it inhibits the proliferation of tumor cells in an opposite way [10, 15] .
Reportedly, WBCs are mainly differentiated from bone marrow hematopoietic stem cells (BMHSCs; e.g. CD34 + SCA1 + BMHSCs). Lung cancer stem cells (LCSCs) are responsible for the initiation, progression, metastasis and relapse of lung cancers (e.g. SP + LCSCs, CD24 + IGF1R + LCSCs and CD133 + LCSCs) [16, 17] . Therefore, the proliferation and numbers of BMHSCs and LCSCs are critical for myelosuppression and lung cancer. As a kind of non-coding RNAs, microRNAs play crucial roles in cell proliferation via regulating the expression of target genes post-transcriptionally [18, 19] . However, the effect of SHSB granule on LCSCs and BMHSCs and the corresponding mechanism at microRNA level are still unclear.
In the present study, nude mice with lung cancer were treated with physiological saline, CTX, or CTX + SHSB granule. Then, LCSCs ratio and BMHSCs ratio were determined. Microarray analysis was performed to study the microRNA profiling of LCSCs and BMHSCs. MicroRNA expressions were further validated using quantitative real time-polymerase chain reaction (qRT-PCR). Our results might shed light on the mechanism and therapeutic targets of SHSB granule in curing myelosuppression from the aspect of microRNAs.
RESULTS

Tumor mass and general blood indexes
Tumor masses in CTX and CTX+SHSB groups were significantly smaller than that in control group 
Cell cycle and proliferation index
Proliferation index of lung cancer cells in CTX+SHSB group was significantly lower than that in CTX and control groups (4-d, 6-d, 8-d and 10-d; P<0.05; Figure 1E ).
Moreover, the proliferation index of BMCs in CTX group was first significantly decreased (4-d; P<0.05) and then increased (6-d, 8-d and 10-d; P<0.05; Figure 1F ) in comparison with that in control group. In contrast, the proliferation index of BMCs in CTX+SHSB group was remarkably higher than that in CTX and control groups (8-d and 10-d; P<0.05; Figure 1F ). Figure 1J and Supplementary Figure 1) . These results were consistent with the results of proliferation index of BMCs ( Figure 1F ). Figure  2A ). Based on Volcano Plot filtering ( Figure 2B ), 49, 5 and 49 DEmiRNAs in LCSCs were found between CTX and control groups, CTX+SHSB and control groups, as well as CTX+SHSB and CTX groups, respectively (Fold change ≥1.5 and P≤0.05; Figure 2C ). A total of 278, 45 and 234 DEmiRNAs in BMHSCs were identified between CTX and control groups, CTX+SHSB and control groups, as well as CTX+SHSB and CTX groups, respectively (Fold change ≥1.5 and P≤0.05; Figure 2C ). Furthermore, ANOVA analysis identified 45 DEmiRNAs (in LCSCs) and 343 DEmiRNAs (in BMHSCs) between the three groups ( Table 1) .
Ratio of stem cells
Confirmation of 12 DEmiRNAs
QRT-PCR was performed to confirm the differential expression of 12 DEmiRNAs (Table 2 and Figure 3 ). As shown in Figure 3 , mmu-miR-32* (Figure 3A) , mmumiR-466i-5p ( Figure 3B ) and mmu-miR-669c ( Figure 3C ) in SP + LCSCs were significantly up-regulated after CTX mmu-miR-466a-5p mmu-miR-466i-5p mmu-miR-881* mmu-miR-106b* mmu-miR-881 mmu-miR-34c* mmu-miR-3071 mmu-miR-122* mmu-miR-1187 mmu-miR-291a-5p
mmu-miR-3082-5p mmu-miR-669k* mmu-miR-669d mmu-miR-3067 mmu-miR-669o-5p
mmu-miR-195* mmu-miR-669e mmu-miR-466c-5p mcmv-miR-m01-2 mmu-miR-669l
mmu-miR-669f-5p mmu-miR-3078* mmu-miR-466b/o-5p mmu-miR-669n mmu-miR-541* mmu-miR-669c mmu-miR-706 mmu-miR-466e-5p mmu-miR-669p* mmu-miR-221*
mmu-miR-3086-3p mmu-let-7d* mmu-miR-300 mmu-miR-721 mmu-miR-466n-3p mmu-miR-29a* mmu-miR-1247 mmu-miR-345-5p mmu-miR-467c* mmu-miR-144 mmu-miR-770-3p mmu-miR-1a-1* mmu-miR-465c-5p mmu-miR-1900 mmu-miR-2861 mmu-miR-34c* mmu-miR-154* mmu-miR-138-2* mmu-miR-3095-3p mmu-miR-493 mmu-miR-22 mmu-miR-101a mmu-miR-1249 mmu-miR-23a* mmu-miR-668* mmu-miR-296-3p mmu-miR-106a mmu-miR-877
mmu-miR-24 mmu-miR-5097 mmu-miR-152 mmu-miR-325* mmu-miR-140 mmu-miR-467e* mmu-miR-145 mmu-miR-290-3p mmu-miR-344g-5p mmu-miR-15a mmu-miR-127 mmu-miR-19b mmu-miR-3104-5p mmu-miR-128-2* mmu-miR-328 mmu-miR-467a* mmu-miR-194-2* mmu-miR-1187 mmu-miR-149 mmu-miR-378 mmu-miR-29c mghv-miR-M1-2-3p mmu-miR-125a-3p mmu-miR-706 mmu-miR-450a
mmu-miR-297a*/c*/-297b-3p In addition, mmu-miR-106b* (Figure 3G ), mmumiR-144 ( Figure 3H ) and mmu-miR-669k* ( Figure 3I ) in CD34 + SCA1 + BMHSCs were down-regulated after CTX treatment. However, these microRNAs were up-regulated after CTX+SHSB treatment. On the contrary, mmu-miR-142-3p ( Figure 3J ), mmu-miR-210 ( Figure 3K ) and mmumiR-223 ( Figure 3L ) in CD34 + SCA1 + BMHSCs were up-regulated after CTX treatment. These microRNAs were down-regulated after CTX+SHSB treatment. These results indicated that SHSB reversed the effects of CTX on microRNAs like mmu-miR-106b*, mmu-miR-144, mmumiR-669k*, mmu-miR-142-3p, mmu-miR-210 and mmumiR-223 in CD34 + SCA1 + BMHSCs.
DISCUSSION
CTX frequently causes myelosuppression [5] , and SHSB granule can cure myelosuppression without promoting the development of lung cancer [11, 12] . However, its mechanism and therapeutic targets are still unclear.
In this study, CTX treatment strongly suppressed tumor growth ( Figure 1A ). CTX decreased SP + LCSCs ratio ( Figure 1G ) and CD133 + LCSCs ratio ( Figure 1I ). Reportedly, alkylating units in the CTX-derived phosmoramide mustard in human can alkylate DNA [20] , and CTX induces cell apoptosis [21, 22] . Our results were consistent with the suppressive effects of CTX on lung cancer [4] . These results also suggested that CTX might suppress lung cancer growth via decreasing SP + LCSCs and CD133 + LCSCs. More importantly, proliferation index of lung cancer cells ( Figure 1E ), SP + LCSCs ratio ( Figure 1G ) and CD24 + IGF1R
+ LCSCs ratio ( Figure 1H ) in CTX+SHSB group were remarkably lower than that in control and CTX groups. These results agreed well with the inhibitory effects of SHSB on the transformation of lung cancer cells from G0/G1 phase to S phase [10] . Also, these results indicated that SHSB granule might suppress the growth of lung cancer via decreasing SP + LCSCs. In the present study, CTX remarkably reduced the number of WBCs ( Figure 1B ). This result was consistent with the fact that CTX could cause myelosuppression [5] . After CTX treatment, declines were found in the proliferation index of BMCs (4-d; Figure 1F ) and CD34 + SCA1
+ BMHSCs ratio ( Figure 1J ). This suggested that CTX might cause myelosuppression via inhibiting the proliferation of CD34 + SCA1 + BMHSCs. In contrast, SHSB granule completely reversed the decrease in WBCs ( Figure 1B ). This agreed well with the fact that SHSB could cure myelosuppression [10] [11] [12] . Especially, SHSB remarkably increased the proliferation index of BMCs ( Figure 1F ) and CD34 + SCA1
+ BMHSCs ratio ( Figure 1J ). As WBCs derived from BMHSCs, our results indicated that SHSB might increase WBCs via promoting the proliferation of CD34 + SCA1 + BMHSCs. As shown in qRT-PCR results, CTX enhanced the expression of mmu-miR-32*, mmu-miR-466i-5p and mmu-miR-669c in SP + LCSCs, and SHSB granule further strengthened their expression ( Figure 3A-3C) . Reportedly, miR-32 is located at 9q31.2 in a region of homozygous deletion in various types of cancer [23] . For instance, it promotes the growth, migration and invasion of colorectal carcinoma cells [24] . Currently, little is known about the role of miR-466i-5p in cancer development. Ionizing radiation can induce apoptosis in cochlea hair cells, and miR-466i-5p in HEI-OC1 cells is significantly up-regulated 12, 24 and 48 h after ionizing radiation [25] . MiR-669c is significantly down-regulated in mice with Bronchiolo-alveolar adenocarcinoma [26] . In this study, the up-regulations of miR-32*, miR-466i-5p and mmu-miR-669c in SP + LCSCs after CTX treatment were consistent with previous studies [23, 25, 26] . Besides, these microRNAs were further up-regulated after CTX+SHSB treatment. This indicated that SHSB might further inhibit SP + LCSCs proliferation via enhancing the expressions of miR-32*, miR-466i-5p and mmumiR-669c.
Moreover, CTX significantly changed the expressions of mmu-miR-106b* (down-regulation), mmu-miR-144 (down-regulation), mmu-miR-669k* (down-regulation), mmu-miR-142-3p (up-regulation), mmu-miR-210 (up-regulation) and mmu-miR-223 (upregulation) in CD34 + SCA1
+ BMHSCs (Figure 3G-3L ). However, SHSB reversed the effects of CTX on these microRNAs (Figure 3G-3L) . Among these microRNAs, little is known about the role of miR-106b*, mmumiR-144 and miR-669k* in proliferation or differentiation of hematopoietic stem cells [27, 28] . In contrast, miR142a-3p accelerates the formation and differentiation of hematopoietic stem cells [29] . MiR-210 level is increased in CD34 + cells in myelodysplastic syndromes, a disease caused by abnormal proliferation and differentiation of hematopoietic stem cells [30] . MiR-223 is preferentially expressed in bone marrow [31] , and it induces human granulopoiesis [32] . Therefore, SHSB might enhance BMHSCs proliferation via up-regulating mmu-miR106b*, mmu-miR-144 and mmu-miR-669k*, as well as down-regulating mmu-miR-142-3p, mmu-miR-210 and mmu-miR-223.
MATERIALS AND METHODS
Animals, cell line, and lung cancer models
Nude mice are immune deficient, and tumor can be easily established in them. Therefore, four-week old male BALB/C nude mice weighted 20±2g were purchased from Shanghai Laboratory Animal Center of Chinese Academy of Sciences [Batch Number: SCXK (Shanghai) 2007-0005]. These mice were bred in the Specific-PathogenFree animal laboratory of Longhua Hospital (Shanghai, China) under a condition of [24] [25] [26] o C, 65-70% humidity and free access to diet and water.
Lung adenocarcinoma is one of the main kinds of lung cancer, and A549 is a cell line of human lung adenocarcinoma. In this study, A549 was obtained from the Shanghai Cell Bank of Chinese Academy of Sciences. A549 cells were cultured in F12k medium supplemented with 10% fetal bovine serum (Gibco, NY, USA). Then, 0.2 ml 1×10 7 /ml A549 cells with high proliferating activity were inoculated into the oxters of nude mice. Lung cancer models were successfully constructed four weeks after inoculation.
Animal grouping and drug administration
The constructed cancer models were randomly divided into three groups, including control group (N=36), CTX group (i.e. CTX group; N=36), and CTX + SHSB granule group (i.e. CTX+SHSB group; N=36).
Since CTX could lead to obvious myelosuppression, we utilized CTX to treat lung cancer to establish a mice model of myelosuppression. CTX was generated from Jiangsu Hengrui Medicine Co., Ltd (Batch Number: H32020857). Before usage, 1 mg/ml CTX was freshly prepared using physiological saline. SHSB granule was obtained from the drug preparation center of Longhua Hospital (Batch Number: Z05170773). SHSB granule was dissolved in double-distilled H 2 O to generate a 2 g/ml SHSB solution. Nude mice in control group were intraperitoneally injected with physiological saline (100 mg/kg/d) for three days, and these mice also took physiological saline (40 g/kg/d) via gastroenteric irrigation for 10 days. Nude mice in CTX group were intraperitoneally injected with CTX (100 mg/kg/d) for three days, and these mice also took physiological saline (40 g/kg/d) via gastroenteric irrigation for 10 days. Nude mice in CTX+SHSB group were intraperitoneally injected with CTX (100 mg/kg/d) for three days, and these mice also took SHSB (40 g/kg/d) via gastroenteric irrigation for 10 days. Intraperitoneal injection and gastroenteric irrigation were started at the same day for all mice. All the animal experiments were approved by the Animal Ethics Committee of Shanghai Longhua Hospital, China.
General blood indexes and tumor mass
Eyeball was removed, and peripheral blood was taken from mice 4, 6, 8 or 10 days after intraperitoneal injection. WBCs, red blood cells and platelets were counted using an automatic blood cell analyzer (DxH 800™; Beckman Coulter Inc., Miami, FL, USA). Thereafter, mice were sacrificed by cutting off their neck under anesthesia. Xenograft tumors were obtained and weighted under a sterile and RNAase-free condition.
Generation of lung cancer cells and BMCs
Lung cancer cells were generated from xenograft tumor ( 
Determination of cell cycle and proliferation index
Lung cancer cells and BMCs were immobilized at 4 o C for 10 h using 70% and absolute ethyl alcohol, respectively. Cells were washed with phosphate buffer solution. RNase A was added (final concentration: 50 μg/ml) to digest RNA at 37 o C for 30 min. Propidium iodide solution was added (final concentration: 65 μg/ml) to stain cells for 30 min. Then, FACSCalibur™ Cell Sorting system (BD Biosciences; Franklin Lakes, NJ, USA) was utilized to perform flow cytometry to determine cell cycle. Based on cell cycle information, proliferation index was calculated using the following formula:
In this formula, G 0 /G 1 , S and G 2 /M represent the relative numbers of cells in phase G 0 /G 1 , S and G 2 /M, respectively. 
Ratio of stem cells
MicroRNA microarray analysis
Flow cytometry was used to isolate SP + LCSCs and CD34 + SCA1
+ BMHSCs from lung cancer cells (8-d) and BMCs (6-d), respectively. For each sample, total RNA was isolated using Trizol Reagent (Invitrogen; CA, USA), and microRNA was purified using miRNeasy mini kit (Qiagen; Valencia, CA, USA). RNA quantity and quality were determined using NanoDrop spectrophotometer (ND-1000; Nano-Drop Technologies; DE, USA). Thereafter, the miRCURY™ Hy3™/Hy5™ Power labeling kit (Exiqon; Vedbaek, Denmark) was utilized to label 1 mg microRNA to miRCURY™ LNA Array (version: 16.0).
Microarray data were normalized using the Quantile method. Differentially expressed microRNAs (DEmiRNAs) between groups were identified via Volcano Plot filtering [criteria: Fold change ≥1.5 and P≤0.05] and analysis of variance (ANOVA; criterion: P≤0.05). Moreover, hierarchical clustering was conducted using the MeV software (v4.6; the institute for genomic research; http://www.tm4.org/mev.html) to determine the specificity of DEmiRNAs between groups. 
qRT-PCR
Statistical analysis
All data were shown in a "mean ± standard deviation" manner and analyzed using Statistical Product and Service Solutions (SPSS; version: 18.0) software. Differences between groups were determined using one-way ANOVA method. Least-Significant-Difference test was utilized under a condition of equal variance. Otherwise, Dunnett's T3 method was used to adjust results. The threshold for statistical difference was set as P<0.05.
CONCLUSION
To sum up, SHSB granule might cure CTXinduced myelosuppression and increase WBCs via enhancing CD34 + SCA1 + BMHSCs proliferation (SHSB granule up-regulated the expressions of mmu-miR106b*, mmu-miR-144 and mmu-miR-669k*, as well as down-regulated the expressions of mmu-miR-142-3p, mmu-miR-210 and mmu-miR-223 in CD34 + SCA1 + BMHSCs). Besides, SHSB granule might also suppress lung cancer progression via inhibiting SP + LCSCs proliferation (SHSB granule up-regulated miR-32*, miR-466i-5p and mmu-miR-669c in SP + LCSCs). These findings might help us to better understand the mechanism of SHSB in curing myelosuppression and blocking lung cancer development. Our results might also provide potential therapeutic targets for treating CTX-caused myelosuppression in patients with lung cancer.
Limitation
In the present study, microRNA profiling was only determined in SP + LCSCs (8-d) and CD34 + SCA1 + BMHSCs (6-d). A time-course microRNA profiling analysis might provide more information. Only the change patterns of 12 microRNAs were detected by using qRT-PCR. Much more microRNAs will be selected to perform qRT-PCR in our future study.
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